Daratumumab-based treatment of monoclonal gammopathy-associated angioedema due to acquired C1-inhibitor deficiency

Remy S Petersen,Lauré M Fijen,Laurens E Franssen,Josephine M I Vos,Danny M Cohn

DOI: https://doi.org/10.1016/j.jacig.2024.100322

2024-08-05

Abstract:Daratumumab-based treatment could control severe, treatment-refractory, life-threatening angioedema due to acquired C1-inhibitor deficiency associated with monoclonal gammopathy.

What problem does this paper attempt to address?

Rituximab in the Treatment of Acquired Angioedema Secondary to Marginal Zone Lymphoma of the Spleen

Kathie Wu,Joseph Vadakara

DOI: https://doi.org/10.7759/cureus.36790

2023-03-28

Cureus

Abstract:Angioedema occurs in less than 1-2% of the population and amongst these cases, those with acquired angioedema are less prevalent than hereditary angioedema. Amongst cases of acquired angioedema, studies have shown that they were highly linked with an associated lymphoproliferative disorder, suspected secondary to the production of neutralizing autoantibodies from pathological B cell proliferation. We present a case of a patient who presented with recurrent episodes of angioedema and was found to have low C4 and C1 esterase function, initially concerning for a hereditary angioedema variant, who was subsequently found to have marginal B cell lymphoma mimicking hereditary angioedema.
Daratumumab as a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathy

Vinay Mathew Thomas,Jeffrey A. Gilreath,Shawn Newton,Kristi J. Smock,Ming Y. Lim

DOI: https://doi.org/10.1111/hae.14323

2021-04-28

Haemophilia

Abstract:<section class="article-section article-section__open-research"><h2><a class="accordion__control" href="#"><span class="section__title">Open Research</span></a></h2><section class="article-section__sub-content"><h1>DATA AVAILABILITY STATEMENT</h1><p>Deidentified data that support the findings of this study are available from the corresponding author upon reasonable request.</p></section></section>

hematology
Successful Treatment with Daratumumab of a Patient with Monoclonal Lambda Light Chain Disease Presenting as Nephrotic Syndrome and Crescentic Glomerulonephritis

Alon Bnaya,Chezi Ganzel,Linda Shavit

DOI: https://doi.org/10.1159/000536283

2024-01-16

Acta Haematologica

Abstract:Introduction: Monoclonal immunoglobulin deposition diseases (MIDDs) are a group of systemic diseases, characterized by deposition of monoclonal immunoglobulin predominantly in the kidney. In the absence of overt hematologic disease, MIDDs are classified as a part of monoclonal gammopathy of renal significance. Patients with MIDD may present with a nephrotic syndrome and kidney function impairment. Treatment usually includes anti-plasma cell therapy. Case Presentation: We report a case of a 54-year-old female who presented with nephrotic syndrome related to light chain deposition disease of lambda type. Due to a complicated clinical course (including cardiac injury and thromboembolic stroke), plasma cell-targeted therapy was stopped. A few months later, the patient presented with severe acute kidney injury. Kidney biopsy revealed crescentic glomerulonephritis, and immunofluorescence staining was positive for lambda chain. Treatment with daratumumab was initiated resulting in stabilization of kidney function and partial nephrotic syndrome remission. Conclusion: This case highlights an uncommon histologic manifestation in a patient diagnosed with light chain deposition disease. Furthermore, it underscores the significance of plasma cell-targeted therapy and the favorable clinical and hematological response observed with daratumumab.

hematology
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.

Efstathios Kastritis,Giovanni Palladini,Monique C. Minnema,Ashutosh D. Wechalekar,Arnaud Jaccard,Hans C. Lee,Vaishali Sanchorawala,Simon Gibbs,Peter Mollee,Christopher P. Venner,Jin Lu,Stefan Schoenland,Moshe E. Gatt,Kenshi Suzuki,Kihyun Kim,M. Teresa Cibeira,Meral Beksac,Edward Libby,Jason Valent,Vania Hungria,Sandy W. Wong,Michael Rosenzweig,Naresh Bumma,Antoine Huart,Meletios A. Dimopoulos,Divaya Bhutani,Adam J. Waxman,Stacey A. Goodman,Jeffrey A. Zonder,Selay Lam,Kevin Song,Timon Hansen,Salomon Manier,Wilfried Roeloffzen,Krzysztof Jamroziak,Fiona Kwok,Chihiro Shimazaki,Jin-Seok Kim,Edvan Crusoe,Tahamtan Ahmadi,NamPhuong Tran,Xiang Qin,Sandra Y. Vasey,Brenda Tromp,Jordan M. Schecter,Brendan M. Weiss,Sen H. Zhuang,Jessica Vermeulen,Giampaolo Merlini,Raymond L. Comenzo

DOI: https://doi.org/10.1056/nejmoa2028631

IF: 158.5

2021-01-01

New England Journal of Medicine

Abstract:BACKGROUND:Systemic immunoglobulin light-chain (AL) amyloidosis is characterized by deposition of amyloid fibrils of light chains produced by clonal CD38+ plasma cells. Daratumumab, a human CD38-targeting antibody, may improve outcomes for this disease.METHODS:We randomly assigned patients with newly diagnosed AL amyloidosis to receive six cycles of bortezomib, cyclophosphamide, and dexamethasone either alone (control group) or with subcutaneous daratumumab followed by single-agent daratumumab every 4 weeks for up to 24 cycles (daratumumab group). The primary end point was a hematologic complete response.RESULTS:A total of 388 patients underwent randomization. The median follow-up was 11.4 months. The percentage of patients who had a hematologic complete response was significantly higher in the daratumumab group than in the control group (53.3% vs. 18.1%) (relative risk ratio, 2.9; 95% confidence interval [CI], 2.1 to 4.1; P<0.001). Survival free from major organ deterioration or hematologic progression favored the daratumumab group (hazard ratio for major organ deterioration, hematologic progression, or death, 0.58; 95% CI, 0.36 to 0.93; P = 0.02). At 6 months, more cardiac and renal responses occurred in the daratumumab group than in the control group (41.5% vs. 22.2% and 53.0% vs. 23.9%, respectively). The four most common grade 3 or 4 adverse events were lymphopenia (13.0% in the daratumumab group and 10.1% in the control group), pneumonia (7.8% and 4.3%, respectively), cardiac failure (6.2% and 4.8%), and diarrhea (5.7% and 3.7%). Systemic administration-related reactions to daratumumab occurred in 7.3% of the patients. A total of 56 patients died (27 in the daratumumab group and 29 in the control group), most due to amyloidosis-related cardiomyopathy.CONCLUSIONS:Among patients with newly diagnosed AL amyloidosis, the addition of daratumumab to bortezomib, cyclophosphamide, and dexamethasone was associated with higher frequencies of hematologic complete response and survival free from major organ deterioration or hematologic progression. (Funded by Janssen Research and Development; ANDROMEDA ClinicalTrials.gov number, NCT03201965.).
The Immunomodulatory Effect and Clinical Efficacy of Daratumumab in a Patient With Cold Agglutinin Disease

Anna Zaninoni,Juri A. Giannotta,Anna Gallì,Rosangela Artuso,Paola Bianchi,Luca Malcovati,Wilma Barcellini,Bruno Fattizzo

DOI: https://doi.org/10.3389/fimmu.2021.649441

IF: 7.3

2021-03-01

Frontiers in Immunology

Abstract:Daratumumab is a monoclonal antibody directed against the transmembrane glycoprotein CD38 expressed on plasma cells and lymphoplasmocytes, with a proven efficacy in multiple myeloma. Here we show its clinical efficacy in a patient with cold agglutinin disease (CAD) relapsed after multiple lines of therapy. CAD is caused by cold reactive autoantibodies that induce complement mediated hemolysis and peripheral circulatory symptoms. The disease is also characterized by the presence of monoclonal IgM gammopathy and of a lymphoid bone marrow infiltration that benefits from B-cell targeting therapies (i.e., rituximab) but also from plasma cell directed therapies, such as proteasome inhibitors. In the patient described, we also show that daratumumab therapy influenced the dynamics of several immunoregulatory cytokine levels (IL-6, IL-10, IL-17, IFN-γ, TNF-α, TGF-β) indicating an immunomodulatory effect of the drug beyond plasma cell depletion. In addition, we provide a literature review on the use of daratumumab in autoimmune conditions, including multi-treated and refractory patients with autoimmune hemolytic anemia (both CAD and warm forms), Evans syndrome (association of autoimmune hemolytic anemia and immune thrombocytopenia) and non-hematologic autoimmune diseases, such as systemic lupus erythematosus and rheumatoid arthritis.

immunology
Deucrictibant for angioedema due to acquired C1-inhibitor deficiency: a randomized-controlled trial

Remy S. Petersen,Lauré M. Fijen,Johannes P. Kelder,Danny M. Cohn

DOI: https://doi.org/10.1016/j.jaci.2024.03.007

IF: 14.29

2024-03-18

Journal of Allergy and Clinical Immunology

Abstract:Background Angioedema due to acquired C1-inhibitor deficiency is a very rare but serious disease, with an estimated prevalence of 1 per 500,000 persons. There are no approved therapies to treat or prevent angioedema swellings in patients with this condition. Deucrictibant is a specific, orally bioavailable, competitive antagonist of the bradykinin B2 receptor currently under investigation for hereditary angioedema. Objective To assess the efficacy and safety of deucrictibant as acute and prophylactic treatment for angioedema due to acquired C1-inhibitor deficiency. Methods A two-part, randomized, double-blind, placebo-controlled crossover study was conducted. In Part 1, four consecutive angioedema attacks were treated with three doses of deucrictibant (10 mg, 20 mg, and 30 mg) or placebo. In Part 2, deucricibant 20 mg or placebo was administered bidaily for two treatment periods of eight weeks. Results Three patients were enrolled of which one completed both study parts and two completed only Part 2. In Part 1, a reduction in attack severity was observed in the three attacks treated with deucrictibant as opposed to an increase in severity of the attack treated with placebo. In Part 2, the individual mean monthly attack rates were 2.0, 0.6 and 1.0 during the placebo period and 0.0 across all patients during treatment with deucrictibant. There were no severe adverse events, and one self-limiting treatment-emergent adverse event (abdominal pain). Conclusions Deucrictibant has the potential to effectively and safely treat and prevent angioedema attacks due to acquired C1-inhibitor deficiency.

immunology,allergy
Promising response of proliferative glomerulonephritis with monoclonal IgG deposits to low-dose daratumumab: a case report

Hongyao Xu,Yao Huang,Ling Dong,Hua Yu,Bo Lin

DOI: https://doi.org/10.3389/fmed.2024.1360979

IF: 3.9

2024-07-24

Frontiers in Medicine

Abstract:Proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) is a rare disease without standardized treatment modalities. Daratumumab is a human IgG monoclonal anti-CD38 antibody that has been demonstrated to be highly effective and safe in the treatment of PGNMID. This article reports a 66-year-old female who suffered from edema in both lower limbs and face for 6 years with mild proteinuria and hypoproteinemia. Renal biopsy displayed eight glomeruli, among which two presented with glomerulosclerosis, and the remaining six exhibited moderate diffuse hyperplasia of glomerular mesangial cells and stroma with endothelial cell proliferation. Immunofluorescence microscopy revealed lumpy and diffuse deposits of C3, C1q, IgG, and κ light chain in the glomerular mesangium, with strongly positive staining for IgG3 and varying degrees of weak to negative staining for IgG1, IgG2, IgG4, and λ light chain. Additionally, ultrastructural analysis unveiled that the glomerular basement membrane was segmentally thickened, accompanied by diffuse pedicle fusion, segmental tethered insertion, subendothelial deposits, and electron-dense material in tethered areas. The patient received a total dose of 800 mg of daratumumab (400 mg daily for two consecutive days), as well as daily prednisone (25 mg) and valsartan (80 mg), for treatment and achieved complete remission after three-month follow-up. This case represents an early attempt to treat PGNMID with low-dose daratumumab but requires long-term follow-up.

medicine, general & internal
Antigen-specific B-cell Depletion for Precision Therapy of Mucosal Pemphigus Vulgaris.

Jinmin Lee,Daniel K. Lundgren,Xuming Mao,Silvio Manfredo-Vieira,Selene Nunez-Cruz,Erik F. Williams,Charles-Antoine Assenmacher,Enrico Radaelli,Sangwook Oh,Baomei Wang,Christoph T. Ellebrecht,Joseph A. Fraietta,Michael C. Milone,Aimee S. Payne

DOI: https://doi.org/10.1172/jci138416

IF: 19.456

2020-01-01

Journal of Clinical Investigation

Abstract:Desmoglein 3 chimeric autoantibody receptor T cells (DSG3-CAART) expressing the pemphigus vulgaris (PV) autoantigen DSG3 fused to CD137-CD3ζ signaling domains, represent a precision cellular immunotherapy approach for antigen-specific B cell depletion. Here, we present definitive preclinical studies enabling a first-in-human trial of DSG3-CAART for mucosal PV. DSG3-CAART specifically lysed human anti-DSG3 B cells from PV patients and demonstrated activity consistent with a threshold dose in vivo, resulting in decreased target cell burden, decreased serum and tissue-bound autoantibodies, and increased DSG3-CAART engraftment. In a PV active immune model with physiologic anti-DSG3 IgG levels, DSG3-CAART inhibited antibody responses against pathogenic DSG3 epitopes and autoantibody binding to epithelial tissues, leading to clinical and histologic resolution of blisters. DSG3 autoantibodies stimulated DSG3-CAART IFN-γ secretion and homotypic clustering, consistent with an activated phenotype. Toxicology screens using primary human cells and high-throughput membrane proteome arrays did not identify off-target cytotoxic interactions. These preclinical data guided the trial design for DSG3-CAART and may help inform CAART preclinical development for other antibody-mediated diseases.
Case report: A case of proliferative glomerulonephritis with monoclonal kappa-light chain deposits treated with daratumumab combination therapy

Jue Wang,Jun-Ting Lv,Dan Xiao,Jia Liu,Jun Du,Lu Zhong

DOI: https://doi.org/10.3389/fmed.2024.1462199

2024-10-02

Abstract:Introduction: Proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) is a chronic glomerular disease caused by monoclonal gammopathy. IgG (mainly IgG3) is the most commonly involved isotype of PGNMID. Here we illustrated a novel medication regimen for the rare variant of PGNMID with deposition of monoclonal immunoglobulin light chain only (PGNMID-LC). Daratumumab has been proved effective in the treatment of plasma cell myeloma while its effect for PGNMID-LC has rarely been reported. Methods: A daratumumab combination therapy (D-VCd regimen, specifically are daratumumab + dexamethasone + bortezomib + cyclophosphamide) was adopted to treat a patient diagnosed with PGNMID-LC. Results: The utility of D-VCd regimen showed a favorable effect in this patient. After the fixed course, his clinical symptom, laboratory parameters, neoplastic plasma cells clonity all restored to normal range, and no obvious disease progression was observed throughout the treatment. After a follow up of 14 months, no significant renal or hematological disease progression has been observed. Conclusion: This case underscores the utility of D-VCd regimen in treatment of PGNMID-LC, and it's inferred that daratumumab regimen has clinical effects in the disease primarily through targeting tumor clonity. However, data on the use of daratumumab (either in monotherapy or in combination) in clinical trials of PGNMID-LC is currently so limited that that more experiments are needed to support the inference.
Excellent response to anti-CD38 therapy with daratumumab in a patient with severe refractory CANOMAD

Elba Pascual-Goñi,Roger Collet,Clara Tejada-Illa,Lorena Martín-Aguilar,Marta Caballero-Ávila,Cinta Lleixà,Silvana Novelli,Jordi López-Pardo,Albert Esquirol Sanfeliu,Anais Mariscal,Yolanda Álvaro Gargallo,Eugenia Martínez-Hernández,Dolores Cocho,Luis Querol

DOI: https://doi.org/10.1136/jnnp-2023-332443

2024-02-10

Abstract:Background Intravenous immunoglobulin (IVIG) and rituximab are considered the first-line and second-line treatments for Chronic Ataxic Neuropathy and Ophthalmoplegia with IgM-paraprotein, cold Agglutinins, and anti-Disialosyl antibodies (CANOMAD), with an overall clinical response around 50%. New anti-CD38 daratumumab, targeting long-lived plasma cells, has been reported as a promising therapy for treatment-refractory antibody-mediated disorders. We report the first case of a severe refractory CANOMAD, successfully treated with daratumumab. Methods A patient in their 70s with severe relapsing CANOMAD, refractory to IVIG, steroids, rituximab and ibrutinib developed severe tetraparesis and respiratory failure. Plasma exchange (PE) improved motor and ventilatory function; however, after 6 weeks, patient remained PE dependent. Intravenous daratumumab was initiated at 16 mg/kg weekly for 3 weeks, every 2 weeks for the second and third month, and monthly afterwards. Results After 3 weeks of starting daratumumab, PE was discontinued and, since then, the patient evolved to complete recovery. Antidisialosyl antibody titres decreased after PE and remained stable during daratumumab. Serum neurofilament light-chain levels were elevated in the exacerbation phase and normalised after daratumumab. The patient remains in clinical remission under monthly daratumumab, 12 months after initiation. Conclusions The first patient with aggressive treatment-refractory CANOMAD treated with daratumumab provides proof-of-principle evidence that daratumumab may be an effective treatment in IgM-related neuropathies.

surgery,psychiatry,clinical neurology
Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease.

Marit Jalink,Chaja F. Jacobs,Jahanzaib Khwaja,Dorothea Evers,Coty Bruggeman,Bruno Fattizzo,Marc Michel,Etienne Crickx,Quentin A. A Hill,Ulrich Jaeger,Arnon P. Kater,Anja B.U. Mäkelburg,Anouk Breedijk,Peter A.W. te te Boekhorst,Marlijn P.A. Hoeks,Masja de de Haas,Shirley P. D'Sa,Josephine M.I. M.I. Vos

DOI: https://doi.org/10.1182/bloodadvances.2024012585

IF: 7.642

2024-03-23

Blood Advances

Abstract:Autoimmune hemolytic anemia (AIHA) is a rare autoantibody-mediated disease. For steroid and/or rituximab-refractory AIHA, there is no consensus on optimal treatment. Daratumumab, a monoclonal antibody targeting CD38, could be beneficial by suppression of CD38+ plasmacells and thus autoantibody secretion. In addition, since CD38 is also expressed by activated T-cells, daratumumab may also act via immunomodulatory effects. We evaluated efficacy and safety of daratumumab monotherapy in an international retrospective study including 19 adult patients with heavily pretreated refractory AIHA. In warm AIHA (wAIHA, n=12), overall response was 50% with a median response duration of 5.5 months (range, 2-12 months) including ongoing response in 2 patients after 6 and 12 months. Of 6 non-responders, 4 had Evans syndrome. In cold AIHA (cAIHA, n=7) overall hemoglobin (Hb) response was 57%, with ongoing response in 3/7 patients. One additional non-anemic cAIHA patient was treated for severe acrocyanosis and reached a clinical acrocyanosis response as well as a Hb increase. Of 6 cAIHA patients with acrocyanosis, 4 had improved symptoms after daratumumab treatment. In two patients with wAIHA treated with daratumumab in whom we prospectively collected blood samples, we found complete CD38 + T cells depletion after daratumumab, as well as altered T-cell subset differentiation and a severely diminished capacity for cell activation and proliferation. Reappearance of CD38+ T-cells coincided with disease relapse in one patient. In conclusion, our data show that daratumumab therapy may be a treatment option for refractory AIHA. The observed immunomodulatory effects that may contribute to the clinical response deserve further exploration.

hematology
Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma

Saad Z Usmani,Hareth Nahi,Maria-Victoria Mateos,Niels W C J van de Donk,Ajai Chari,Jonathan L Kaufman,Philippe Moreau,Albert Oriol,Torben Plesner,Lotfi Benboubker,Peter Hellemans,Tara Masterson,Pamela L Clemens,Man Luo,Kevin Liu,Jesus San-Miguel

DOI: https://doi.org/10.1182/blood.2019000667

IF: 20.3

2019-08-22

Blood

Abstract:Daratumumab, a human monoclonal antibody targeting CD38, is approved as monotherapy and in combination regimens for patients with multiple myeloma (MM). Currently, daratumumab is administered IV. The phase 1b PAVO (MMY1004) study evaluated subcutaneously administered daratumumab in combination with the recombinant human hyaluronidase PH20 enzyme (rHuPH20) in patients with relapsed or refractory MM. Part 1 of the study, reported here, evaluated a mix-and-deliver (MD) formulation of daratumumab and rHuPH20 (DARA-MD) administered by subcutaneous infusion. Patients received subcutaneous daratumumab according to the approved IV monotherapy dosing schedule at 1200 mg (n = 8) or 1800 mg (n = 45). Primary end points were safety and pharmacokinetic (PK) variables. The most common treatment-emergent adverse events with DARA-MD 1200 mg were thrombocytopenia, upper respiratory tract infection, insomnia, and decreased appetite (37.5% each). Anemia (33.3%), upper respiratory tract infection, pyrexia, and diarrhea (26.7% each) were the most common treatment-emergent adverse events with DARA-MD 1800 mg. One patient in the 1200-mg dose group (12.5%) and 11 patients in the 1800-mg dose group (24.4%) experienced infusion-related reactions, which were generally grade 1/2 and typically occurred at the first infusion. The 1800 mg dose achieved similar or greater serum concentrations compared with the 16 mg/kg IV dose. Overall response rates of 25.0% and 42.2% were achieved with 1200-mg and 1800-mg DARA-MD, respectively. Subcutaneous administration of DARA-MD was well tolerated in patients with relapsed or refractory MM, with the 1800-mg dose exhibiting PK concentrations and responses consistent with IV daratumumab in a similar patient population. This study was registered at www.clinicaltrials.gov as #NCT02519452.
Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma

Marije B Overdijk,Sandra Verploegen,Marijn Bögels,Marjolein van Egmond,Jeroen J Lammerts van Bueren,Tuna Mutis,Richard WJ Groen,Esther Breij,Anton CM Martens,Wim K Bleeker,Paul WHI Parren

DOI: https://doi.org/10.1080/19420862.2015.1007813

2015-03-04

mAbs

Abstract:Daratumumab (DARA) is a human CD38-specific IgG1 antibody that is in clinical development for the treatment of multiple myeloma (MM). The potential for IgG1 antibodies to induce macrophage-mediated phagocytosis, in combination with the known presence of macrophages in the tumor microenvironment in MM and other hematological tumors, led us to investigate the contribution of antibody-dependent, macrophage-mediated phagocytosis to DARA's mechanism of action. Live cell imaging revealed that DARA efficiently induced macrophage-mediated phagocytosis, in which individual macrophages rapidly and sequentially engulfed multiple tumor cells. DARA-dependent phagocytosis by mouse and human macrophages was also observed in an in vitro flow cytometry assay, using a range of MM and Burkitt's lymphoma cell lines. Phagocytosis contributed to DARA's anti-tumor activity in vivo, in both a subcutaneous and an intravenous leukemic xenograft mouse model. Finally, DARA was shown to induce macrophage-mediated phagocytosis of MM cells isolated from 11 of 12 MM patients that showed variable levels of CD38 expression. In summary, we demonstrate that phagocytosis is a fast, potent and clinically relevant mechanism of action that may contribute to the therapeutic activity of DARA in multiple myeloma and potentially other hematological tumors.

medicine, research & experimental
Daratumumab therapy for post-HSCT immune-mediated cytopenia: experiences from two pediatric cases and review of literature

Lina Driouk,Robert Schmitt,Anke Peters,Sabine Heine,Hermann Josef Girschick,Brigitte Strahm,Charlotte M Niemeyer,Carsten Speckmann

DOI: https://doi.org/10.1186/s40348-021-00114-y

2021-04-29

Abstract:Background: Immune-mediated cytopenias (AIC) are challenging complications following allogeneic hematopoietic stem cell transplantation (HSCT). While broad-acting immunosuppressive agents like corticosteroids are often standard of care, several novel therapies which target specific immunological pathways have recently been developed and provide hope for patients with steroid-refractory courses and may limit long-term toxicity. The successful off-label use of the plasma cell depleting anti-CD38 antibody daratumumab was published in several case reports, suggesting efficacy, i.e., in patients with antibody-mediated AIC refractory to previous B cell depletion. We want to share our experience with two children, whom we treated with daratumumab, including one fatal course with uncontrolled disease. Given the absence of substantial data from HSCT registries or prospective trials, we furthermore provide a critical review of the literature on daratumumab treatment of AIC. Case presentations: Patient 1 (P1), an 11-year-old girl with lipopolysaccharide-responsive and beige-like anchor protein (LRBA) deficiency who developed immune-mediated thrombocytopenia (AIT) from day +58 after HSCT, showed a complete response to daratumumab after the fourth of six total daratumumab doses. She remains transfusion independent for over a year of follow-up. Previously, her thrombocytopenia was refractory to corticosteroids, rituximab, intravenous immunoglobulins (IVIG), eltrombopag, cyclosporine A, and sirolimus. Patient 2 (P2), a 6-year-old boy with CD40 ligand (CD40L) deficiency, developed both AIT and hemolytic anemia (AIHA) after HSCT on days +58 and +83, respectively, and was also treated with daratumumab after being previously refractory to prednisolone, rituximab, and IVIG. Yet, he did neither respond to daratumumab nor the concomitantly administered methyprednisolone pulse, plasmapheresis, and eculizumab and succumbed due to refractory disease. Conclusion: Reviewing the literature on the use of daratumumab for refractory AIC post-HSCT, we consider daratumumab a promising agent for this life-threatening disorder: ten of the twelve patients reached transfusion independency in the literature. However, treatment failures are likely to be underreported. Thus, controlled trials are needed to explore the safety and efficacy of daratumumab in this rare post-HSCT complication.
Where we are with acquired angioedema due to C1 inhibitor deficiency: A systematic literature review

Yiyun Shi,Chen Wang

DOI: https://doi.org/10.1016/j.clim.2021.108819

IF: 10.19

2021-09-01

Clinical Immunology

Abstract:Acquired angioedema due to C1 inhibitor deficiency (C1-INH-AAE) is a rare disease characterized by adult-onset recurrent non-urticarial angioedema with low levels of C1-INH. It is associated with lymphoproliferative disorders, and treatments are off-label with variable success. We conducted a systematic literature review to include patients with C1-INH-AAE identified in PubMed and Embase databases between January 2006 and February 2021. Clinical features of these patients were summarized, and factors associated with disease remission were explored. A total of 121 patients were included in the current study with a median age at diagnosis of 64 years and 45.5% being male. An associated disease was recorded in 94 patients (77.7%), and lymphoproliferative disorder was the most reported (59/94, 62.8%). Anti-C1-INH autoantibodies were present in 45 of 71 patients (63.4%). Factors impacting disease remissions included age (odds ratio [OR] 0.951, 95% confidence interval [CI] 0.909–0.994, p = 0.027), male (OR 0.327, 95% CI 0.124–0.866, p = 0.025), presence of monoclonal gammopathy (OR 0.133, 95% CI 0.041–0.429, p = 0.001), requirement of specific on-demand treatment (OR 0.216, 95% CI 0.066–0.709, p = 0.012) and rituximab use (OR 2.865, 95% CI 1.038–7.911, p = 0.042). A total of nine patients (7.4%) died at last follow up and most were unrelated to C1-INH-AAE. Our results imply that C1-INH-AAE is primarily associated with underlying B or plasma cell abnormalities, and clone-directed therapies could be promising options for its long-term management.

immunology
Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis

Foteini Theodorakakou,Meletios A. Dimopoulos,Efstathios Kastritis

DOI: https://doi.org/10.1177/20406207211058334

2021-01-01

Therapeutic Advances in Hematology

Abstract:Primary systemic immunoglobulin light chain (AL) amyloidosis is caused by a plasma cell clone of, usually low, malignant potential that expresses CD38 molecules on their surface. Treatment of AL amyloidosis is based on the elimination of the plasma cell clone. The combination of cyclophosphamide–bortezomib–dexamethasone (CyBorD) is the most widely used and is considered a standard of care; however, complete hematologic response rates and organ response rates remain unsatisfactory. Daratumumab, an anti-CD38 monoclonal antibody, has demonstrated encouraging results, with rapid and deep responses, in patients with relapsed or refractory AL amyloidosis as monotherapy with a favorable toxicity profile. The large phase-III, randomized, ANDROMEDA study evaluated the addition of daratumumab to CyBorD in previously untreated patients with AL amyloidosis and demonstrated that addition of daratumumab can substantially improve hematologic complete response rates, survival free from major organ deterioration or hematologic progression, and organ responses. In this review, we discuss the role of daratumumab in the treatment of AL amyloidosis, its mechanism of action, and the results of ANDROMEDA study that led to the first approved therapy for AL amyloidosis.

hematology
Monoclonal Antibodies in the Treatment of Multiple Myeloma

Niels W C J van de Donk,Sonja Zweegman

DOI: https://doi.org/10.1016/j.hoc.2023.12.002

Abstract:The incorporation of monoclonal antibodies into backbone regimens has substantially improved the clinical outcomes of patients with newly diagnosed and relapsed/refractory multiple myeloma (MM). Although the SLAMF7-targeting antibody elotuzumab has no single- agent activity, there is clinical synergy between elotuzumab and immunomodulatory drugs in patients with relapsed/refractory disease. Daratumumab and isatuximab are CD38-targeting antibodies which have single-agent activity and a favorable safety profile, which make these agents an attractive component of combination regimens. Monoclonal antibodies may cause infusion-related reactions, but with subcutaneous administration these are less frequently observed. All therapeutic antibodies may interfere with assessment of complete response. Next-generation Fc-engineered monoclonal antibodies are in development with the potential to further improve the outcome of patients with MM.
Case Report: Daratumumab in a Patient With Severe Refractory Anti-NMDA Receptor Encephalitis

Dominica Ratuszny,Thomas Skripuletz,Florian Wegner,Matthias Groß,Christine Falk,Roland Jacobs,Heiner Ruschulte,Martin Stangel,Kurt-Wolfram Sühs

DOI: https://doi.org/10.3389/fneur.2020.602102

IF: 3.4

2020-12-22

Frontiers in Neurology

Abstract:Anti-NMDA receptor encephalitis is the most common type of antibody mediated autoimmune encephalitis (AIE). Patients often develop neuropsychiatric symptoms and seizures, women are affected about four times more than men, and in about 50% the disease is associated with a neoplasia, especially teratomas of the ovary. We describe the case of a 20-year-old woman suffering from a severe therapy refractory course of anti-NMDA receptor encephalitis. Treatment included glucocorticoids, plasma exchange, intravenous immunoglobulins, rituximab, and bortezomib without clinical improvement. Due to a therapy refractive course 28 weeks after disease onset, the patient received 10 cycles of daratumumab. Therapy escalation was performed with the anti-CD38 monoclonal antibody daratumumab as off label treatment, based on the therapy of refractory myeloma and led to an improvement of her clinical status. She spent about 200 days on the intensive care unit, followed by several weeks on the intermediate care unit with close follow ups every 4–6 weeks afterward. During follow-up, the patient was able to resume everyday and self-care activities, reflected by the modified Rankin scale (mRS) and Barthel index. Because this disease is potentially life threatening and can lead to irreversible brain atrophy, development of further therapy strategies are of great importance. Our case describes a successful treatment for therapy refractory anti-NMDA receptor encephalitis using the anti-CD38 antibody daratumumab.

neurosciences,clinical neurology
Daratumumab for the treatment of relapsed and refractory multiple myeloma

Miao-jie SHI,Peng LIU

DOI: https://doi.org/10.13683/j.wph.2017.03.014

2017-01-01

Abstract:Relapsed and refractory multiple myeloma (RRMM) is a rapidly progressive disease with short survival period.The daratumumab,a CD38 monoclonal antibody has been approved by American food and drug administration (FDA) for RRMM treatment.Either monotherapy or combination therapy of daratumumab can significantly improve the prognosis of RRMM patient.Daratumumab has faster and longer curative effect with higher safety.This review describes research progress of daratumumab for RRMM treatment.
Daratumumab treatment in six highly sensitised solid organ transplant recipients: A case series and literature review

Richard Lemal,Lucie Blandin,Charlotte Uro‐Coste,Carole Philipponnet,Etienne Geoffroy,Anne‐Elisabeth Heng,Cyril Garrouste,Paul Rouzaire

DOI: https://doi.org/10.1111/tan.15458

2024-04-11

HLA

Abstract:We report data on six kidney or heart recipients who were administered daratumumab to treat or prevent antibody‐mediated rejection (ABMR). To date, data are scarce concerning the use of daratumumab in solid organ transplantation and most reports show a decrease in donor‐specific antigen (DSA) levels and an improvement in ABMR using a multiple myeloma daratumumab administration scheme, that is, with sequential systematic administration. Here, we report on the efficacy of daratumumab 1/ in reducing the histological signs of ABMR, 2/ in reducing the ability of DSA to bind to donor cells in vitro through negativation of flow cytometry crossmatching, 3/ in preferentially being directed towards antibodies sharing epitopes, suggesting that daratumumab may specifically target activated plasma cells, 4/ and when administered as a single dose. This last point suggests, for the first time, that, as for rituximab in auto‐immune diseases, the scheme for daratumumab administration could be different for targeting DSA‐producing plasma cells than for tumour cells.

pathology,immunology,cell biology

Daratumumab-based treatment of monoclonal gammopathy-associated angioedema due to acquired C1-inhibitor deficiency

Rituximab in the Treatment of Acquired Angioedema Secondary to Marginal Zone Lymphoma of the Spleen

Daratumumab as a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathy

Successful Treatment with Daratumumab of a Patient with Monoclonal Lambda Light Chain Disease Presenting as Nephrotic Syndrome and Crescentic Glomerulonephritis

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.

The Immunomodulatory Effect and Clinical Efficacy of Daratumumab in a Patient With Cold Agglutinin Disease

Deucrictibant for angioedema due to acquired C1-inhibitor deficiency: a randomized-controlled trial

Promising response of proliferative glomerulonephritis with monoclonal IgG deposits to low-dose daratumumab: a case report

Antigen-specific B-cell Depletion for Precision Therapy of Mucosal Pemphigus Vulgaris.

Case report: A case of proliferative glomerulonephritis with monoclonal kappa-light chain deposits treated with daratumumab combination therapy

Excellent response to anti-CD38 therapy with daratumumab in a patient with severe refractory CANOMAD

Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease.

Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma

Daratumumab therapy for post-HSCT immune-mediated cytopenia: experiences from two pediatric cases and review of literature

Where we are with acquired angioedema due to C1 inhibitor deficiency: A systematic literature review

Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis

Monoclonal Antibodies in the Treatment of Multiple Myeloma

Case Report: Daratumumab in a Patient With Severe Refractory Anti-NMDA Receptor Encephalitis

Daratumumab for the treatment of relapsed and refractory multiple myeloma

Daratumumab treatment in six highly sensitised solid organ transplant recipients: A case series and literature review